Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy

Satoshi Watanabe1 | Takeshi Ota2 | Masachika Hayashi1 | Hiroyuki Ishikawa3 | Aya Otsubo1 | Satoshi Shoji1 | Koichiro Nozaki1 | Kosuke Ichikawa1 | Rie Kondo1 | Takao Miyabayashi4 | Satoru Miura5 | Hiroshi Tanaka5 | Tetsuya Abe6 | Masaaki Okajima7 | Masaki Terada7 | Takashi Ishida8 | Akira Iwashima9 | Kazuhiro Sato10 | Hirohsa Yoshizawa11 | Toshiaki Kikuchi1

1Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
2Niigata Prefectural Shibata Hospital, Niigata, Japan
3Department of Diagnostic Radiology, Niigata University Medical and Dental Hospital, Niigata, Japan
4Niigata City General Hospital, Niigata, Japan
5Niigata Cancer Center Hospital, Niigata, Japan
6Shinrakuen Hospital, Niigata, Japan
7Saiseikai Niigata Hospital, Niigata, Japan
8Niigata Prefectural Central Hospital, Joetsu, Japan
9Nagaoka Chuo General Hospital, Nagaoka, Japan
10Nagaoka Red Cross Hospital, Nagaoka, Japan
11Niigata Medical Center, Niigata, Japan

Abstract

Background: Interstitial lung disease (ILD) induced by anti-programmed-cell death-1 (PD-1) and anti-PD-ligand 1 (PD-L1) is potentially life-threatening and is a common reason of the discontinuation of therapy. In contrast, an enhancement in antitumor effects was reported in patients who developed immune-related adverse events, including ILD. Although recent evidence suggests that radiologic patterns of ILD may reflect the severity of ILD and the antitumor immune responses to anti-PD-1/PD-L1 therapies, the association between radiologic features and clinical outcomes remains unclear.

Methods: Patients with advanced non-small-cell lung cancer who were treated with 1st to 3rd line anti-PD-1 therapy from January 2016 through October 2017 were identified at multiple institutions belonging to the Niigata Lung Cancer Treatment Group. ILD was diagnosed by the treating physicians, and chest computed tomography scans were independently reviewed to assess the radiologic features of ILD.

Results: A total of 231 patients who received anti-PD-1 therapy were enrolled. Thirty-one patients (14%) developed ILD. Sixteen patients were classified as having ground glass opacities (GGO), 16 were classified as having cryptogenic organizing pneumonia (COP), and one was classified as having pneumonitis not otherwise specified. Patients with GGO had significantly worse overall survival time compared to patients with COP (7.8 months (95% CI: 2.2-NE) versus not reached (95% CI: 13.2-NE); \(P = 0.0175\)). Multivariate analysis of all 231 patients also revealed that PS = 1 and ≥2 and GGO were significant predictors of a worse overall survival.

Abbreviations: COP, cryptogenic organizing pneumonia; GGO, ground glass opacities; ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; irAEs, immune-related adverse events; NOS, not otherwise specified; NSCLC, non-small-cell lung cancer; OS, overall survival; PD-1, programmed-cell death-1; PD-L1, PD-ligand 1; PFS, progression-free survival.
Immune checkpoint inhibitors (ICIs), including anti-programmed-cell death-1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies, have demonstrated promising and durable benefits in non-small-cell lung cancer (NSCLC) patients. Anti-PD-1 and anti-PD-L1 antibodies have become the new standard of care for NSCLC patients. Because interactions between PD-L1 and PD-1 maintain immune tolerance to normal tissues peripherally, blockade of PD-L1 and PD-1 results in the activation of the immune system and often causes immune-related adverse events (irAEs). Previous studies have shown that clinical efficacies of anti-PD-1/PD-L1 therapies were augmented in patients with irAEs, suggesting that anti-PD-1/PD-L1 antibodies are capable of stimulating immune responses against both normal cells and tumor cells.

Previous phase III studies have reported that the incidence of interstitial lung disease (ILD) induced by anti-PD-1/PD-L1 therapies was 1%-6%. ILD is potentially fatal and often results in the discontinuation of therapy. Indeed, several studies have shown that ILD was the most common irAE leading to the discontinuation of anti-PD-1 therapies. On the other hand, the augmentation of antitumor effects was reported in patients with ILD, similar to other irAEs.

Several radiologic patterns of ILD caused by ICIs have been reported. Although these radiologic patterns may reflect the severity of ILD and the antitumor immune response enhanced by anti-PD-1/PD-L1 therapies, the correlation between radiologic patterns and clinical outcomes, especially the augmentation of antitumor effects, remains unclear. The aim of this study is to elucidate the correlation between the radiologic features of ILD induced by anti-PD-1 antibodies and clinical course of patients with advanced NSCLC.

For all patients, the following data were collected retrospectively: demographics, oncologic therapy including anti-PD-1 therapy, and irAEs. For patients with ILD, the clinical features of ILD and treatment for ILD were obtained. ILD was diagnosed by the treating physicians. The chest computed tomography (CT) scans of patients with ILD were obtained and independently reviewed by two pulmonologists and one radiologist blinded to patient clinical data. ILD was classified into 5 subtypes: cryptogenic organizing pneumonia (COP), ground glass opacities (GGO), interstitial, hypersensitivity and pneumonitis not otherwise specified (NOS) according to previous reports. If there was disagreement, a consensus read was performed. ILD was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Progression-free survival (PFS) was calculated from the start of anti-PD-1 therapy until progressive disease or death due to any cause. Overall survival (OS) was measured as the time between the start date of anti-PD-1 therapy and death due to any cause.

Kaplan-Meier survival curves were constructed for PFS and OS, and differences between groups were identified using the log-rank test. Continuous variables are presented as the median (range) and were compared by two-sided t tests. Categorical variables were compared by Fisher’s exact test or chi-square test. To evaluate prognostic factors for OS, we used multivariate Cox proportional hazards models. Multivariable analysis was performed, including age, sex, smoking status, histology, Eastern Cooperative Oncology Group performance status, irAE and radiologic features. To minimize lead-time bias associated with time-dependent factors, we performed landmark analysis including only patients.
who were alive or whose disease was under control at 43 days after anti-PD-1 therapy, which is the median time of onset of ILD, for OS (n = 214) and PFS (n = 172). Additionally, we performed landmark analysis at 6 weeks after anti-PD-1 therapy to evaluate the difference in OS between patients with and those without irAE using multivariate Cox proportional hazards models. All the reported p-values were 2-sided, and P < 0.05 was considered significant. Statistical analysis was performed using JMP 9.0.2 statistical software (SAS Institute, Cary, NC).

3 | RESULTS

3.1 | Patient characteristics

Overall, 231 patients were enrolled in this study. Among these patients, 33 patients (14%) developed ILD (CONSORT diagram [Figure 1]). Baseline characteristics at the initiation of anti-PD-1 therapy for patients with and those without ILD are presented in Table 1. The frequency of squamous carcinoma was significantly higher in patients with ILD than in patients without ILD. There were no significant differences in terms of age, sex, smoking status, Eastern Cooperative Oncology Group performance status, line of anti-PD-1 therapy and type of anti-PD-1 antibody.

3.2 | Radiographic patterns of ILD and OS

The Kaplan-Meier curves for PFS for patients with and without ILD are shown in Figure 2A. The median PFS among patients with ILD was significantly longer than that among patients without ILD (not reached (95% CI: 7.8-NE) vs 8.6 months (95% CI: 5.9-13.4); P = 0.0322). However, similar OS times were observed between patients with ILD and those without ILD (14.8 months (95% CI: 7.8-NE) vs 24.5 months (95% CI: 19.6-NE); P = 0.6113) (Figure 2B).

3.3 | Baseline characteristics in patients with ILD

Of 33 patients with ILD, 16 were classified as having GGO, 16 were classified as having COP, and one was classified as having pneumonitis NOS (Table 1). Representative chest CT scans of patients with GGO, COP and pneumonitis NOS are shown in Figure S1. Table 2 presents the characteristics of patients with ILD. The number of patients who received nivolumab was significantly higher in patients with COP than in those with GGO (P = 0.0068). Patients with GGO received anti-PD-1 therapy earlier than those with COP (P = 0.0055). The expression levels of PD-L1 on tumor cells were significantly higher in patients with GGO than those with COP and pneumonitis NOS (Table 1). No significant differences in terms of age, sex, smoking status, Eastern Cooperative Oncology Group performance status, line of anti-PD-1 therapy and type of anti-PD-1 antibody were observed between patients with ILD and those without ILD.

3.4 | Radiographic patterns of ILD and OS

The Kaplan-Meier survival curves for patients with COP, GGO and pneumonitis NOS are shown in Figure 3A. The OS was significantly worse among patients with GGO than among those with COP (7.8 months (95% CI: 2.2-NE) versus not reached (95% CI: 13.2-NE); P = 0.0175). There were no significant difference in PFS between patients with GGO and those with COP (7.6 months (95% CI: 0.9-NE) versus not reached (95% CI: 2.9-NE); P = 0.1602) (Figure S2). Previous studies indicated that the use of steroids at baseline decreased the clinical benefit of anti-PD-1 therapy.19 Thus, we evaluated whether steroid administration for the treatment of ILD decreased the antitumor effects of anti-PD-1 therapy.19 Steroid therapies for ILD did not affect the survival times (10.1 months (95% CI: 3.1-NE) versus not reached (95% CI: 5.3-NE); P = 0.3202) (Figure 3B). Because a correlation between the development of irAEs and a clinical efficacy of anti-PD-1 therapy was reported, we assessed OS in patients with irAE other than ILD.7,8 The OS for patients with irAE other than ILD was significantly better than that for patients with ILD (not reached (95% CI: NE-NE) versus 14.8 (95% CI: 7.6-NE); P = 0.0052) (Figure 3C). As shown in Table 2, the median time of onset of ILD was significantly earlier in patients with GGO than in patients with COP; thus, we evaluated OS after the onset of ILD (Figure 3D). The OS after the onset of ILD in patients with GGO tended to be shorter than...
that in patients with COP (7.3 months (95% CI: 1.7-NE) versus not reached (95% CI: 5.5-NE); \( P = 0.0503 \)).

### 3.5 | Survival factors

In the multivariate analysis of 231 patients, PS = 1 and \( \geq 2 \) and GGO were identified as significant predictors of a shorter overall survival time (hazard ratio: 5.4926 (95% CI: 2.3723-15.9777); \( P < 0.0001 \), hazard ratio: 21.7533 (95% CI: 8.6118-66.7892); \( P < 0.0001 \) and hazard ratio: 7.3029 (95% CI: 2.636-20.2552); \( P = 0.0003 \) (Table 3). Similar to a previous report, the presence of any irAE was significantly correlated with prolonged OS (hazard ratio: 0.2692 (95% CI: 0.1117-0.5455); \( P = 0.0001 \)).

### 4 | DISCUSSION

The current study demonstrated the relationship between the radiologic patterns of ILD caused by anti-PD-1 therapy and OS in NSCLC patients. Patients with GGO had a significantly
worse survival time than those with COP (Figure 3A). Multivariate analysis also demonstrated that the development of GGO was significantly correlated with poor prognosis (Table 3). In contrast, COP was not correlated with OS (Table 3). Previous studies did not clearly show the association between the development of ILD and patient outcomes after anti-PD-1 therapy. Fujimoto et al reported that NSCLC patients with ILD had longer PFS with nivolumab therapy.10 On the other hand, Shresh et al showed that the development of ILD decreased survival in NSCLC.20 Our study demonstrated that patients with ILD exhibited prolonged PFS; however, patients with ILD had similar OS compared to patients without ILD (Figure 2A and B). Anti-PD-1 therapies cause several types of radiologic patterns of ILD, and our results indicate that patients with ILD could be divided into good and poor prognosis groups according to radiologic features. As there is no laboratory test to determine the severity of ILD, we must consider intensive therapy for ILD based on clinical findings, including cough, fever, dyspnea and hypoxemia. Our findings on the correlation between radiologic patterns and clinical outcomes will help physicians make decisions regarding the administration of steroids and immunosuppressants for ILD.

There are several possible explanations for the worse prognosis of patients with GGO. The time of onset of GGO was significantly earlier than that of COP, and the median treatment cycles of anti-PD-1 therapy tended to be shorter in patients with GGO than in patients with COP (Table 2). Moreover, 12 out of 16 patients with GGO discontinued anti-PD-1 therapy after no more than 3 cycles. The relationship between the discontinuation of PD-L1/PD-1 therapy and poor outcome has been indicated previously.21,22 Early discontinuation of anti-PD-1 therapy could be correlated with worse prognosis in patients with GGO. Another explanation may be the exposure to systemic steroids. Patients with GGO were treated with steroids significantly more frequently than patients with COP (Table 2). Although our data did not demonstrate that steroid therapy decrease OS among patients with ILD, previous studies have demonstrated that patients treated with systemic steroid during the first cycle of nivolumab had a shorter survival time (Figure 3B).19

Previous studies have also demonstrated that patients with irAEs have a more favorable prognosis than patients without irAEs.7,8 Similar to these studies, the current study showed that patients with irAEs other than ILD had significantly better survival times compared to patients with ILD (Figure 3C).

The limitations of the current study include a relatively small number of patients with ILD and its retrospective nature. Although all medical records of consecutive NSCLC patients receiving anti-PD-1 therapy were assessed, radiology review was performed with only clinically determined ILD cases, not all cases treated with anti-PD-1 therapy. In our study, no patients were diagnosed with ILD based on pathological evidence.

To the best of our knowledge, this is the first report to demonstrate the correlation between radiologic features of ILD and OS in NSCLC patients. Our findings suggest that patients with GGO require intensive therapy more often than patients with COP. A prospective study is required to establish the treatment strategy for ILD according to radiologic patterns. The fact that some patients with GGO responded to anti-PD-1 therapy indicates that damage to normal lung tissues might be different even in patients with similar radiologic features of ILD. Evaluation of lung tissues from patients with ILD and assessment of the correlation between radiologic patterns and histology are warranted.

ACKNOWLEDGMENTS

The authors thank the patients, their families, all study investigators and Hiroko Aita for their contributions to the study.

CONFLICT OF INTEREST

Dr Watanabe received lecture fees from Eli Lilly, Pfizer, Novartis Pharma, AstraZeneca, Chugai Pharma, Bristol-Myers, Boehringer Ingelheim, MSD, Ono Pharmaceutical, Daiichi Sankyo and Taiho Pharmaceutical; Dr Ota received lecture fees from Boehringer Ingelheim, MSD, Eli Lilly, AstraZeneca and Chugai Pharma; Dr Hayashi received lecture fees from AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Daiichi Sankyo, Taiho Pharmaceutical and Actelion Pharmaceuticals Japan; Dr Ishikawa received lecture fees from Daiichi Sankyo, Bayer, Nihon Medi-Physics
**TABLE 2  Characteristics for patients with ILD**

| Patient characteristics | COP (n = 16) | GGO (n = 16) | NOS (n = 1) | P value<sup>a</sup> |
|-------------------------|-------------|--------------|-------------|---------------------|
| Median age, years (range) | 67 (60-79) | 65 (45-82) | 77 | .3106<sup>b</sup> |
| Sex | Female/male | 4/12 | 2/14 | 1/0 | .6539<sup>c</sup> |
| Smoking status | Current or former | 13 | 16 | 0 | .2258<sup>c</sup> |
| | Never | 3 | 0 | 1 | |
| PS | 0 or 1 | 13 | 11 | 1 | .6851<sup>c</sup> |
| | ≥2 | 3 | 4 | 0 | |
| | Unknown | 0 | 1 | 0 | |
| Type of PD-1 therapy | Nivolumab | 16 | 9 | 0 | .0068<sup>c</sup> |
| | Pembrolizumab | 0 | 7 | 1 | |
| Line of anti-PD-1 therapy, n (%) | 1 | 0 | 6 | 1 | .0055<sup>d</sup> |
| | 2 | 12 | 4 | 0 | |
| | 3 | 4 | 6 | 0 | |
| PD-L1 expression, n (%) | <1 | 1 | 0 | 0 | .0496<sup>d</sup> |
| | 1%-49% | 0 | 1 | 0 | |
| | ≥50% | 1 | 6 | 0 | |
| | Unknown | 14 | 9 | 1 | |
| Median treatment cycles (range) | 9 (1-27) | 2 (1-44) | 2 | .1155<sup>b</sup> |
| Median time of onset of ILD, days (range) | 117 (1-340) | 21 (5-523) | 34 | .041<sup>b</sup> |
| Steroid therapy | Yes | 6 | 13 | 1 | .029<sup>c</sup> |
| | No | 10 | 3 | 0 | |
| Response evaluation | ORR | 44% | 31% | NE | .716<sup>c</sup> |
| | DCR | 81% | 50% | NE | .1351<sup>c</sup> |
| Grade | 1-2 | 14 | 9 | 1 | .1134<sup>c</sup> |
| | ≥3 | 2 | 7 | 0 | |
| Other irAEs | Yes | 3 | 6 | 1 | .4331<sup>c</sup> |
| | No | 13 | 10 | 0 | |
| Subsequent chemotherapy after PD-1 | Yes | 5 | 7 | 0 | .716<sup>c</sup> |
| | No | 11 | 9 | 1 | |

Abbreviations: COP, cryptogenic organizing pneumonia; DCR, disease control rate; GGO, ground glass opacities; ILD, interstitial lung disease; irAE, immune-related adverse events; NE, not evaluable; NOS, not otherwise specified; ORR, overall response rate; PD-1, programmed-cell death-1; PD-L1, PD-ligand 1; PS, performance status.

<sup>a</sup>Patient with COP and GGO are compared. Differences between groups were identified using
<sup>b</sup>student’s t test
<sup>c</sup>Fisher’s exact test
<sup>d</sup>Chi-Square test.

and AstraZeneca; Dr Shoji received lecture fees from AstraZeneca, Chugai Pharma, Taiho Pharmaceutical and MSD; Dr Nozaki received lecture fees from Bristol-Myers, Pfizer and Novartis; Dr Ichikawa received lecture fees from AstraZeneca, Chugai Pharma, Bristol-Myers, Boehringer Ingelheim, Ono Pharmaceutical and Taiho Pharmaceutical; Dr Miyabayashi received lecture fees from Chugai Pharma, Ono Pharmaceutical, AstraZeneca and Actelion Pharmaceuticals; Dr Miura received lecture fees from Bristol-Myers, Ono Pharmaceutical, Boehringer Ingelheim, Eli Lilly, MSD, Chugai Pharma, AstraZeneca, Taiho Pharmaceutical, Kyowa Hakko Kirin and Mochida Pharmaceutical; Dr Tanaka received lecture fees and grants from Bristol-Myers, Eli Lilly, MSD, Taiho Pharmaceutical, Pfizer, Chugai Pharma, Ono Pharmaceutical, AstraZeneca, Boehringer Ingelheim, lecture fees from Novartis and grant from Merck Serono; Dr Abe received lecture fees from AstraZeneca, Chugai Pharma, Boehringer Ingelheim, Eli Lilly, Taiho Pharmaceutical and Bristol-Myers; Dr Okajima received lecture fees from AstraZeneca, Ono Pharmaceutical, Bristol-Myers, Boehringer...
Ingelheim, MSD and Taiho Pharmaceutical; Dr Terada received lecture fees from AstraZeneca, Chugai Pharma, Bristol-Myers, Boehringer Ingelheim, Taiho Pharmaceutical, MSD and Ono Pharmaceutical; Dr Ishida received lecture fees from Boehringer Ingelheim, Bristol-Myers, Eli Lilly and AstraZeneca; Dr Iwashima received lecture fees from AstraZeneca, Chugai Pharma, Bristol-Myers, Boehringer Ingelheim, Taiho Pharmaceutical, MSD, Ono Pharmaceutical, Novartis, Actelion Pharmaceuticals, Torii Pharmaceutical and KYORIN Pharmaceutical; Dr Sato received lecture fees from AstraZeneca, Boehringer Ingelheim, Ono Pharmaceutical, MSD and Pfizer; Dr Yoshizawa received lecture fees from AstraZeneca, Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharma and Ono Pharmaceutical; Dr Kikuchi received grant and lecture fees from Boehringer Ingelheim, Eli Lilly, MSD, Taiho Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, AstraZeneca, Shionogi, TEIJIN PHARMA and KYORIN Pharmaceutical, and lecture fees from Astellas Pharma, Bristol-Myers, Pfizer, Taisho Toyama Pharmaceutical, Janssen Pharmaceutical, Japan BCG Laboratory Novartis, Mylan NV and Roche Diagnostics. All remaining authors have declared no conflicts of interest.

**TABLE 3** Multivariate analysis by cox proportional hazards model

| Characteristic                  | Hazard ratio | 95% CI          | P value |
|---------------------------------|--------------|-----------------|---------|
| Sex (ref = male)                |              |                 |         |
| Female                          | 0.6764       | 0.3234-1.3294   | .2651   |
| Age (ref = <74)                 |              |                 |         |
| ≥75 years                       | 1.1144       | 0.6129-1.9323   | .712    |
| Smoking history (ref = never-smoker) |     |                 |         |
| Current or former               | 1.5687       | 0.683-3.8502    | .2959   |
| Histologic subtype (ref = nonsquamous) | |                 |         |
| Squamous                        | 1.1205       | 0.6548-1.8915   | .674    |
| PS (ref = 0)                    |              |                 |         |
| 1                               | 5.4926       | 2.3723-15.9777  | <.0001  |
| ≥2                              | 21.7533      | 8.6118-66.7892  | <.0001  |
| Radiologic features (ref = no ILD) |             |                 |         |
| COP                             | 1.4384       | 0.4175-4.5114   | .5459   |
| GGO                             | 7.3029       | 2.636-20.2552   | .0003   |
| irAE (ref = no irAE)            |              |                 |         |
| Yes                             | 0.2692       | 0.1117-0.5455   | .0001   |

Abbreviations: CI, confidence interval; COP, cryptogenic organizing pneumonia; GGO, ground glass opacities; ILD, interstitial lung disease; irAE, immune-related adverse events; PS, performance status.

**FIGURE 3** The overall survival curves among patients with COP, GGO, and NOS (A), with or without steroid therapy (B), with ILD or with irAE other than ILD (C). The overall survival curves after the onset of ILD in patients with COP, GGO, and NOS (D). COP, cryptogenic organizing pneumonia; GGO, ground glass opacities; ILD, interstitial lung disease; NOS, not otherwise specified.
WATANABE ET AL.

REFERENCES

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
3. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387:1540-1550.
4. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
7. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374-378.
8. Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018;45:156-163.
9. Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721-1728.
10. Fujimoto D, Yoshioka H, Kataoka Y, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study. Lung Cancer. 2018;119:14-20.
11. Nakashima K, Naito T, Omori S, et al. Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma. J Thorac Oncol. 2016;11:432-433.
12. Sano T, Uharu H, Mikoshiba Y, et al. Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol. 2016;46:270-272.
13. Nishino M, Ramaiai NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051-6060.
14. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709-717.
15. Baba T, Sakai F, Kato T, et al. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol. 2019;15:1911-1920.
16. Palmucci S, Roccasalva F, Puglisi S, et al. Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging. 2014;5:347-364.
17. Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol. 2015;84:542-546.
18. Kadoch MA, Cham MD, Beasley MB, et al. Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol. 2015;44:15-25.
19. Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13:1771-1775.
20. Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14:494-502.
21. Tachihiara M, Negoro S, Inoue T, et al. Prognostic significance of the radiologic classification system. J Thorac Oncol. 2018;13:1771-1775.
22. Tachihara M, Negoro S, Inoue T, et al. Efficacy of anti-PD-1/ PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer. 2018;18:946.
23. Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13:1771-1775.
24. Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14:494-502.
25. Kierski D, Wai ES, Croteau N, et al. Efficacy of nivolumab and pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis. Clin Lung Cancer. 2019;20:e97-e106.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Watanabe S, Ota T, Hayashi M, et al. Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy. Cancer Med. 2020;9:3070-3077. https://doi.org/10.1002/cam4.2974